<DOC>
	<DOCNO>NCT01772056</DOCNO>
	<brief_summary>The relapsing nature atopic dermatitis ( AD ) present challenge long-term treatment . Efficacy safety corticosteroid proven acute treatment AD , efficacy security reduce prevent relapse . Objectives To investigate long-term management ( 16 week ) AD fluticasone propionate ( FP ) 0,05 % cream twice weekly addition emollient ( vehicle ) stabilization acute flare AD FP cream .</brief_summary>
	<brief_title>Efficacy Study Topical Twice Weekly Fluticasone Treatment Reduce Relapse Atopic Dermatitis Children</brief_title>
	<detailed_description>Patients 2-10 year age history mild moderate AD eligible multicentre , randomize , double-blind , control study present acute flare AD ( &lt; 30 % affect body surface area ; head ) . After successful treatment flare acute phase , patient receive either , FP twice weekly plus vehicle vehicle alone 16-week maintenance phase . The primary study end point probability relapse AD occurring . We conduct survivor analysis result .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Children , age 2 10 year , mild moderate acute flare AD ( SCORAD 50 ) treatment episode AD . write informed consent patient ' parent . &gt; 30 % affect body surface area AD . Head affect . Fluticasone vehicle allergy . Patients medical condition topical corticosteroid contraindicate Patients dermatological condition may prevent accurate assessment AD Patients receive concomitant medication might affect study 's outcome . Other medical history could interfere evaluation study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Dermatitis , Atopic</keyword>
	<keyword>Randomized Controlled Trial</keyword>
	<keyword>Child</keyword>
	<keyword>Fluticasone</keyword>
	<keyword>Preventive therapy</keyword>
</DOC>